New Medicines Decisions for May 2024

remdesivir (Veklury®)				
SMC Drug ID	Conditions	Decision	Date of ADTC	Date of decision / Expected date of decision

SMC2550	treatment of COVID-19 in: adults and paediatric patients (at least 4 weeks of age and weighing at least 3 kg) with pneumonia requiring supplemental oxygen (low- or high-flow oxygen or other non-invasive ventilation at start of treatment). adults and paediatric patients (weighing at least 40 kg) who do not require supplemental oxygen and who are at increased risk of progressing to severe COVID-19. SMC restriction: as an option for treating COVID-19 in hospitals in adults, only if they have a high risk of serious illness (risk factors as defined in section 5 of NICE's technology appraisal of nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19). babies, children and young people, only if they: - are aged 4 weeks to 17 years and weigh at least 3 kg, and have pneumonia and need supplemental oxygen, or - weigh at least 40 kg and have a high risk of serious illness (risk factors as defined in section 5 of NICE's technology appraisal guidance on nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19).	Not routinely available as the ADTC is waiting for further advice from local clinical experts	15/05/2024	26/07/2024
Other Decision Specified :				
Web Link : https://www.scottishmedicines.org.uk/media/8316/20240510-collaborative-advice-document-remdesivir-v11.pdf				

tixagevimab and cilgavimab (Evusheld®)

SMC Drug ID	Conditions	Decision	Date of ADTC	Date of decision / Expected date

New Medicines Decisions for May 2024

				of decision
SMC2558	treatment of COVID-19 in adults who do not require supplemental oxygen and who are at increased risk of progressing to severe COVID-19.	Not routinely available as not recommended for use in NHS Scotland	15/05/2024	
Other Decision Specified :				
Web Link : https://www.scottishmedicines.org.uk/media/8315/20240508-collaborative-advice-document-tixagevimab-and-cilgavimab-v10.pdf				

budesonide/formoterol (Symbicort® Turbohaler®)

SMC Drug ID	Conditions	Decision	Date of ADTC	Date of decision / Expected date of decision
SMC2622	As reliever therapy for adults and adolescents (12 years and older) with mild asthma. SMC restriction: for use in patients who would otherwise receive low dose inhaled corticosteroid (ICS) maintenance therapy plus short-acting beta-2 adrenoceptor agonist (SABA) as needed.	Not routinely available as the ADTC is waiting for further advice from local clinical experts	15/05/2024	26/07/2024
Other Decision Specified :				
Web Link : https://www.scottishmedicines.org.uk/media/8313/budesonide-formoterol-symbicort-final-april-2024-for-website.pdf				

New Medicines Decisions for May 2024

ruxolitinib (Opzelura®)				
SMC Drug ID	**Conditions**	**Decision**	**Date of ADTC**	**Date of decision / Expected date of decision**
SMC2634	for the treatment of non-segmental vitiligo (NSV) with facial involvement in adults and adolescents from 12 years of age.	Not routinely available as not recommended for use in NHS Scotland	15/05/2024	
Other Decision Specified :				
Web Link : https://www.scottishmedicines.org.uk/media/8317/ruxolitinib-topical-opzelura-final-april-2024-amended-080524-for-website.pdf				

zanubrutinib (Brukinsa®)				
SMC Drug ID	**Conditions**	**Decision**	**Date of ADTC**	**Date of decision / Expected date of decision**
SMC2671	in combination with obinutuzumab for the treatment of adult patients with refractory or relapsed follicular lymphoma (FL) who have received at least two prior systemic therapies.	Not routinely available as not recommended for use in NHS Scotland	15/05/2024	
Other Decision Specified : SMC Non Submission				
Web Link : https://www.scottishmedicines.org.uk/medicines-advice/zanubrutinib-brukinsa-nonsub-smc2671/				